Losartan Mechanism of Action: The Full Pathway From Angiotensinogen to End-Organ Protection

The Renin-Angiotensin-Aldosterone System: Where Losartan Intervenes

Losartan targets the final step in the renin-angiotensin-aldosterone system (RAAS), blocking angiotensin II at the receptor level rather than preventing its formation. This distinction separates ARBs from ACE inhibitors and carries real pharmacological consequences.

The RAAS cascade begins when juxtaglomerular cells in the kidney release renin in response to decreased renal perfusion pressure, sympathetic nervous system activation, or reduced sodium delivery to the macula densa 1. Renin cleaves angiotensinogen, a 452-amino-acid glycoprotein produced mainly by the liver, into the decapeptide angiotensin I. Angiotensin-converting enzyme (ACE), concentrated on pulmonary and renal endothelial surfaces, then removes two amino acids to generate the octapeptide angiotensin II 2.

Angiotensin II is the primary effector of the RAAS. It acts through two G protein-coupled receptor subtypes: AT1 and AT2. Virtually all of the pathological cardiovascular effects of angiotensin II, including vasoconstriction, aldosterone secretion, sympathetic facilitation, cardiac hypertrophy, and vascular remodeling, are mediated through AT1 3. Losartan sits at exactly this point. It does not reduce circulating angiotensin II; it blocks the receptor that translates angiotensin II into disease.

AT1 Receptor Blockade: How Losartan Binds and What That Binding Does

Losartan binds the AT1 receptor competitively. Its active metabolite EXP-3174 binds insurmountably, meaning that even rising concentrations of angiotensin II cannot fully displace it from the receptor.

The AT1 receptor is a 359-amino-acid, seven-transmembrane-domain receptor coupled primarily to Gq/11 proteins. When angiotensin II binds AT1, phospholipase C is activated, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the sarcoplasmic reticulum, producing smooth muscle contraction and vasoconstriction. DAG activates protein kinase C, which drives cellular proliferation and fibrosis pathways 4.

Losartan inserts into the binding pocket of AT1 with an IC50 of approximately 20 nM. EXP-3174 is 10 to 40 times more potent, with slower dissociation kinetics that produce the insurmountable blockade pattern observed in isolated tissue preparations 5. The clinical significance: EXP-3174 maintains receptor occupancy even as reflex increases in renin raise circulating angiotensin II levels by two to threefold during chronic therapy.

AT1 blockade by losartan produces four immediate downstream effects. Blood vessels relax. Aldosterone secretion from the adrenal zona glomerulosa decreases, reducing sodium and water retention. Sympathetic neurotransmitter release diminishes at postganglionic nerve terminals. And the direct pro-growth signaling through AT1 in cardiac myocytes and vascular smooth muscle cells is interrupted 3.

The AT2 Receptor: Unblocked and Potentially Protective

Because losartan is selective for AT1, the AT2 receptor remains available for angiotensin II binding. During losartan therapy, angiotensin II levels rise (a pharmacological reflex). That surplus angiotensin II is redirected toward unblocked AT2 receptors.

AT2 activation produces effects that oppose AT1 signaling. The receptor couples to Gi proteins and protein phosphatases, promoting vasodilation through nitric oxide and bradykinin release, inhibiting cellular proliferation, and stimulating apoptosis in pathologically hypertrophied cells 6. In rodent models, AT2 stimulation reduced cardiac fibrosis after myocardial infarction by 30 to 40% compared to controls 6.

Whether AT2-mediated effects explain the clinical advantages of ARBs over ACE inhibitors in specific populations remains debated. The 2003 Cochrane review of ARBs versus ACE inhibitors found comparable blood pressure reduction, but the LIFE trial demonstrated stroke risk reduction with losartan that was not explained by blood pressure differences alone 7. The AT2 pathway is one plausible contributor to that "beyond blood pressure" benefit.

EXP-3174: The Metabolite That Does Most of the Work

Losartan is a prodrug in practical terms. After oral administration, roughly 14% of the dose is converted by hepatic cytochrome P450 enzymes (primarily CYP2C9, with contribution from CYP3A4) into EXP-3174, a carboxylic acid metabolite 8.

EXP-3174 is not just more potent. It has different binding characteristics. While losartan shows competitive, surmountable antagonism in functional assays, EXP-3174 demonstrates insurmountable antagonism, shifting the angiotensin II dose-response curve downward rather than simply rightward 5. The practical difference: EXP-3174 maintains efficacy even as the body compensates by producing more angiotensin II.

The parent compound reaches peak plasma concentration in about one hour and has a half-life of approximately two hours. EXP-3174 peaks at three to four hours and maintains a half-life of six to nine hours, which is why once-daily dosing produces adequate 24-hour blood pressure control in most patients 9.

CYP2C9 polymorphisms matter here. Patients carrying the CYP2C9*3 allele (approximately 3.3% of Caucasians, 2.5% of African Americans) show reduced conversion to EXP-3174, which may diminish clinical response. A 2004 pharmacogenomic study in 31 hypertensive patients demonstrated that CYP2C9 poor metabolizers had 50% lower EXP-3174 AUC values and a smaller reduction in diastolic blood pressure compared to extensive metabolizers 10.

Uricosuric Activity: A Mechanism Unique to Losartan Among ARBs

Losartan inhibits the urate transporter URAT1 (SLC22A12) in the proximal renal tubule. No other marketed ARB has this property at clinical doses. The result is increased urinary uric acid excretion and a 0.4 to 0.7 mg/dL reduction in serum uric acid levels during chronic therapy 11.

This is not merely academic. Hyperuricemia is independently associated with cardiovascular events, and a post hoc analysis of the LIFE trial showed that 29% of the cardiovascular benefit of losartan over atenolol was attributable to serum uric acid reduction 12. Dr. Sverre Kjeldsen, a LIFE investigator, stated: "The uric acid lowering effect of losartan appears to contribute meaningfully to the cardiovascular outcome difference observed in LIFE" 12.

The uricosuric effect is specific to the parent compound losartan, not EXP-3174. It occurs at the brush border membrane of proximal tubular cells, where losartan competes with uric acid for reabsorption via URAT1 and possibly the organic anion transporter OAT4 11.

Renal Protection: Efferent Arteriolar Dilation and Beyond

In the kidney, angiotensin II preferentially constricts the efferent arteriole of the glomerulus, maintaining intraglomerular pressure even when systemic pressure drops. This mechanism becomes pathological in diabetic nephropathy, chronic kidney disease, and hypertensive nephrosclerosis: sustained high intraglomerular pressure damages the filtration barrier and accelerates proteinuria 13.

Losartan blocks AT1 on efferent arteriolar smooth muscle, reducing intraglomerular pressure. The RENAAL trial (N=1,513) demonstrated that losartan 100 mg daily reduced the risk of doubling of serum creatinine by 25% and end-stage renal disease by 28% in patients with type 2 diabetes and nephropathy, independent of blood pressure reduction 13. The 2012 KDIGO Clinical Practice Guideline for CKD recommends ARBs or ACE inhibitors as first-line therapy for proteinuric CKD specifically because of this hemodynamic mechanism 14.

Beyond hemodynamics, AT1 blockade reduces transforming growth factor-beta (TGF-β) expression in mesangial cells, which slows the extracellular matrix accumulation that drives glomerulosclerosis. In the RENAAL trial, losartan reduced proteinuria by 35% within the first six months, a reduction that preceded and predicted the long-term renal benefit 13.

Cardiac Protection: Regression of Left Ventricular Hypertrophy

Left ventricular hypertrophy (LVH) is both a consequence of chronic hypertension and an independent predictor of cardiovascular events. Angiotensin II directly stimulates cardiac myocyte hypertrophy and fibroblast collagen synthesis through AT1, independent of its hemodynamic effects 15.

The LIFE trial (Losartan Intervention For Endpoint reduction, N=9,193) randomized patients with hypertension and ECG-documented LVH to losartan-based or atenolol-based therapy and followed them for a mean of 4.8 years. Despite similar blood pressure reduction in both arms, losartan produced a 13% reduction in the primary composite endpoint of cardiovascular death, stroke, or myocardial infarction (p=0.021). The stroke reduction was particularly striking: 25% lower risk with losartan (p=0.001) 7.

The mechanism appears to involve direct anti-hypertrophic and anti-fibrotic effects of AT1 blockade on the myocardium. Echocardiographic substudies of LIFE demonstrated greater regression of left ventricular mass index with losartan than atenolol, again beyond what blood pressure reduction alone would predict 15. As the LIFE investigators reported: "The greater reduction in cardiovascular morbidity and death with losartan was not attributable to the difference in blood pressure reduction" 7.

Vascular and Anti-Inflammatory Effects

AT1 receptor activation increases NADPH oxidase activity in the vascular wall, generating superoxide anions that quench nitric oxide and promote endothelial dysfunction 16. Losartan interrupts this oxidative cascade. In a randomized crossover study of 20 hypertensive patients, losartan 100 mg improved flow-mediated dilation by 39% after eight weeks, a marker of restored endothelial nitric oxide availability 17.

AT1 blockade also reduces vascular inflammation. Angiotensin II upregulates nuclear factor-κB (NF-κB), vascular cell adhesion molecule-1 (VCAM-1), and monocyte chemoattractant protein-1 (MCP-1), all of which promote atherosclerotic plaque formation and instability. In animal models, losartan reduced atherosclerotic lesion area by 44% independent of blood pressure, an effect attributed to reduced macrophage infiltration and NF-κB suppression 16.

These anti-inflammatory properties are relevant to the stroke benefit seen in LIFE. Stroke risk is driven not only by hemodynamics but by plaque instability and endothelial dysfunction, both of which losartan addresses through AT1-mediated pathways that beta-blockers do not target.

Pharmacokinetics: Absorption, Distribution, and Elimination

Losartan is absorbed rapidly from the gastrointestinal tract after oral dosing, with absolute bioavailability of approximately 33% due to extensive first-pass hepatic metabolism 9. Food slows absorption but does not reduce total bioavailability. Both losartan and EXP-3174 are more than 98% bound to plasma proteins, primarily albumin.

The drug distributes with a volume of distribution of approximately 34 liters for losartan and 12 liters for EXP-3174. Neither compound crosses the blood-brain barrier to a significant extent. Elimination is primarily biliary for EXP-3174, with about 60% of an oral dose recovered in feces and 35% in urine 9.

No dose adjustment is required for renal impairment unless the patient is volume-depleted. Hepatic impairment reduces first-pass metabolism and increases both losartan and EXP-3174 exposure. The FDA label recommends a starting dose of 25 mg in patients with hepatic dysfunction 9.

Clinical Pharmacology: From Receptor Binding to Blood Pressure Reduction

After a single 100 mg oral dose, peak antihypertensive effect occurs at approximately six hours (corresponding to peak EXP-3174 levels) and persists for 24 hours. The trough-to-peak ratio is approximately 70%, which the FDA considers adequate for once-daily dosing 9.

Losartan 50 to 100 mg once daily typically reduces systolic blood pressure by 8 to 12 mmHg and diastolic blood pressure by 6 to 8 mmHg at trough, with greater reductions in salt-sensitive and volume-expanded patients. The dose-response curve plateaus around 100 mg; higher doses do not produce additional blood pressure lowering 9.

Reflex tachycardia is minimal because losartan does not activate baroreceptor-mediated sympathetic reflexes to the same degree as direct vasodilators. Plasma renin activity increases two to threefold during chronic therapy, which is expected and confirms adequate RAAS blockade. Aldosterone levels initially fall but may partially escape during long-term use, a phenomenon called aldosterone breakthrough that occurs in 20 to 40% of patients on ARB or ACE inhibitor monotherapy 18.